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LETTER
Structural basis of interaction
between the hepatitis C virus p7 channel
and its blocker hexamethylene amiloride
Dear Editor,
Hepatitis C virus (HCV) infection, which causes hepatitis C
and can chronically lead to serious and life-threatening dis-
eases including liver cirrhosis and hepatocellular carcinoma
(Lauer and Walker, 2001), is a rising global health problem.
More than 170 million people are infected by HCV worldwide
and 3–4 million people are infected each year. No effective
vaccines are available to prevent HCV infection. Moreover,
HCV is a fast mutating RNA virus with seven distinct geno-
types and many subtypes within each genotype. The high
degree of genetic diversity can lead to further viral resistance
to the current therapies within individual patients (Li et al.,
2012). Hence, there remains a strong desire in the medical
community to explore new therapeutic opportunities.
p7, the only viroporin encoded by the HCV genome, is a
63-residue protein that oligomerizes in membrane to form ion
channels with cation selectivity (Moradpour and Penin,
2013). The p7 channel has been shown to facilitate efﬁcient
assembly and release of infectious virions, thus has been
sought after as a potential anti-HCV drug target. Several
inhibitors have been found to inhibit p7 channel activity with
varying efﬁcacies, including the amantadine and rimantadine
(Grifﬁn et al., 2003) that also block the inﬂuenza M2 channel
(Pielak et al., 2011), hexamethylene amiloride (HMA)
(Premkumar et al., 2004), and the long-alkyl-chain imi-
nosugar derivatives (Pavlovic et al., 2005). Another novel
small molecule known as BIT225, which has partial struc-
tural resemblance to HMA, also inhibits p7 activity and has
been pursued as an anti-HCV drug candidate in clinical trials
(Luscombe et al., 2010).
For many years, the inhibition mechanism of the known
p7 inhibitors remained elusive in the absence of a high-
resolution p7 structure. Previous solution NMR studies
revealed that the adamantane compounds bind to six
equivalent hydrophobic pockets (due to the 6-fold symmetry
of the p7 hexamer) near the kink of the central pore-forming
helices, consisting of elements from different helical seg-
ments and from different subunits (OuYang et al., 2013). A
more recent study showed that insertion of rimantadine into
these pockets could function as “molecular wedge” that
attenuates conformational breathing needed for cation ﬂow
through the N-terminal constriction of the p7 channel (Dev
et al., 2015). In addition to the studies on the p7 hexamer, a
combined NMR and modeling study modeled the binding of
rimantadine and several new compounds in the context of a
p7 heptamer complex (Foster et al., 2014). Compared to
rimantadine, HMA has a completely different chemical
structure and was reported to inhibit p7 channel in different
genotypes with stronger inhibition at similar drug concen-
tration (Grifﬁn et al., 2008). Earlier NMR titrations showed
that HMA caused larger chemical shift perturbations in the
loop region, while amantadine and NN-DNJ have a larger
effect on the chemical shifts of the terminal regions (Cook
et al., 2013). Therefore, HMA may act on a different site of p7
than rimantadine, and it is of substantial interest to identify
this binding site.
Here, we capitalized on the NMR system of the p7
channel from genotype 5a, designated p7 (5a) and used a
combination of NMR titration and nuclear Overhauser
enhancement (NOE) experiments to characterize HMA
binding to the p7 channel. We used 100 µmol/L p7 (5a)
(monomer concentration) solubilized in 20 mmol/L DPC and
recorded good quality 1H-13C HSQC spectra of the methyl
groups and 1H-15N TROSY-HSQC spectra of the backbone
amine at various drug concentrations. NMR titration experi-
ment showed that titrating the p7 channel with HMA had no
effects on the methyl groups of Val25 and Val26 (Fig. 1A),
which are key constituents of the rimantadine binding pocket
(OuYang et al., 2013). In contrast, rimantadine titration
strongly perturbed the Val25 resonance (Fig. 1A). Remark-
ably, HMA titration induced chemical shift changes at the
N-terminal constriction of the channel (marked by Val5 and
Ile6), very similar to those caused by rimantadine binding.
The methyl HSQC spectra show that the two different com-
pounds perturbed the Cγ1H3 of Val5 (Fig. 1B) and the Cδ1H3
of Ile6 (Fig. 1C) with essentially the same pattern. Moreover,
the overall chemical shift change patterns in the 1H-15N
TROSY-HSQC spectra induced by HMA and rimantadine
are also very similar (Fig. S1).
We then performed more direct experiments to accurately
pinpoint the HMA binding site by measuring protein-drug
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NOEs. Detection of HMA-speciﬁc NOEs was made possible
by using a sample that contains (15N, 2H)-labeled p7 (5a)
and deuterated or “NMR invisible” DPC. The 3D 15N-edited
NOESY-TROSY-HSQC spectrum of this sample showed
strong HMA NOE crosspeaks corresponding to the hexam-
ethylene for Leu24, Trp48, Leu52, and Val53 and weaker
hexamethylene NOE crosspeaks for Thr27 and Lys33
(Fig. 1D). Our earlier NMR investigation of rimantadine
binding to p7 (5a) observed NOE crosspeaks between the
adamantane protons and the amide protons of Val26, Leu56,
and Arg57 (OuYang et al., 2013). The differences in inter-
molecular NOE patterns between HMA and rimantadine are
consistent with the differences in NMR titration data between
the two inhibitors shown in Fig. 1A. Altogether, the NMR data
indicate that HMA binds to a different site compared to the
one that adamantane compounds bind to. We could not
detect any NOEs to the NH2 groups of HMA due to fast
solvent exchange, and thus the orientation of the bound
HMA could not be determined using the NOE data.
MD simulation was subsequently used to more accurately
position and orient the HMA in the NMR-derived binding site
by optimizing physical interactions. Six HMA molecules were
placed in the 14 × 14 × 14 Å3 box containing the p7 (5a)
channel embedded in neutral POPC bilayer such that the
position of the hexamethylene moiety of each of the HMAs
satisﬁes the observed intermolecular NOEs. After 50 ns of
MD simulation, the positions of HMAs did not change sig-
niﬁcantly, although the orientation became more deﬁned
(Fig. 2A–C). The hydrophobic hexamethylene ring binds to
the above-mentioned pocket consisting of Trp48, Leu52, and
Val53 from H3 of the i monomer, Lys 33 from H2 of the i + 1
monomer, and Leu24 and Thr27 from H2 of i + 2 monomer
(Fig. 2D), and the position of hexamethylene overall agrees
with the NOE data. The monitored distances between the
heavy atoms (carbons and nitrogens) during the simulation
are approximately equal to the NOE-derived distances
(∼4 Å) plus 2 Å. The amiloride moiety of HMA points away
from the bilayer core into the solvent exposed region near
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Figure 1. NMR characterization of HMA binding site. (A–C) Rimantadine and HMA titrations using 1H-13C HSQC as a readout.
Uniformly (13C, 15N)-labeled p7 (5a) (monomer concentration at 0.1 mmol/L) reconstituted in 20 mmol/L DPC was titrated with 0 (red),
1 (orange), 2 (green), 4 (blue), and 8 mmol/L (purple) rimantadine and HMA. Spectra were recorded on a 600 MHz spectrometer. The
resolved peaks are labeled with assignments and the arrows indicate the movement of peaks. Shown in the boxes are gamma methyl
resonances of Val25 (A), gamma methyl resonances of Val5 (B), and delta methyl resonances of Ile6 (C). (D) NOESY experiment
identifying the binding site. Representative strips from the three-dimensional 15N-edited NOESY-TROSY-HSQC spectrum (300 ms
NOE mixing time) recorded using a sample containing (2H,15N)-labeled p7 (5a) and 2 mmol/L HMA, showing HMA NOEs to the
backbone amide protons of Leu24, Thr27, Lys33, Trp48, Leu52, and Val53.
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the wider opening of the channel cavity (Fig. 2D). The
structural data of HMA binding to p7 (5a) allow for modeling
the HMA binding site in p7 (1a), for which HMA inhibition of
the channel activity has been experimentally shown
(Premkumar et al., 2004). Based on the sequence alignment
(Fig. S2A), we used the NMR structure of p7 (5a) (PDB ID:
2M6X) as a template and developed a 3D structural model of
p7 (1a) via Discovery Studio 4.0 (DassaultSystèmesBIOVIA,
2015) by “segment matching” and “coordinate reconstruc-
tion” approach (Fig. S2B). As in the case of p7 (5a), we
performed 50 ns of MD simulation using the p7 (1a) model.
The results show that p7 (1a) forms a hydrophobic binding
pocket for HMA very similar to that observed in p7 (5a)
(Fig. S2C).
Our NMR and MD results show that HMA and rimantadine
bind to different but nearby peripheral pockets of the p7
channel. Although the NMR data was collected for the p7
(5a), the high sequence identity between 5a and 1a and the
fact that the p7 (5a) residues involved in HMA binding are
mostly conserved in p7 (1a) provided us with strong conﬁ-
dence that the HMA binding site reported in this study is
relevant to the identiﬁed HMA inhibition and likely applicable
to other p7 variants. The binding of HMA and rimantadine
both involve anchoring of their hydrophobic groups to a
hydrophobic pocket adjacent to the channel cavity. In both
cases, the binding site is not inside the channel cavity and
thus there are six equivalent binding sites due to the six-fold
symmetry of the p7 channel. Overall, HMA binding can be
characterized by insertion of the relatively ﬂat HMA molecule
into a crevice near the wider mouth of the channel cavity
where the hydrophobic hexamethylene interacts with the
hydrophobic pocket deep inside the crevice and the polar
amiloride ﬁlls the solvent accessible portion of the crevice
(Fig. 2D). We note that previous studies of drug binding of p7
using a heptameric hairpin structure model yielded different
peripheral binding sites for inhibitors. The differences
between the two models might relate to the genotypes and
sample environment. However, some key residues are
conserved in both models, for example, Trp48 and Leu52
(Foster et al., 2014).
Although different binding sites, NMR chemical shift per-
turbation data in Fig. 1A–C indicate that the two inhibitors
induce very similar long-range conformational changes near
the narrow opening of the cavity. For both inhibitors, the
binding site is far away from the narrow end of the cavity. In
fact, compared to the rimantadine binding site, the HMA site
is even farther away. We thus hypothesize that the mecha-
nism of inhibition by HMA is also allosteric, either by
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Figure 2. MD simulation reﬁnement of HMA binding site. (A) The binding energy between HMA and other surrounding materials
in complex system. (B) RMSD value of heavy atoms between the sampled conformations and the starting conformation of HMA
during the 50 ns MD production simulation. (C) The distances between the three key carbons of hexamethylene ring of HMA (the
three key carbons, C1, C2, and C3, were indicated in HMA structure) and the backbone N atoms of residues L24, K33, W48, L52, and
V53 were monitored during the 50 ns MD production simulation. (The monitored distances between carbon and N atoms are
approximately equal to the NOEs data plus 2 Å). (D) Comparison between adamantane binding site and HMA binding site of HCV p7
channels. Left panel: The peripheral pockets that wrap around the adamantane cage of rimantadine (orange) and the hexamethylene
group of HMA (yellow). Right panel: A representative pocket of HMA binding among six equivalent pockets in the p7 hexamer. (E) The
MD simulation result showing the hydrophobic interactions and the polar interactions between HMA and p7 (5a).
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restricting movement of helices needed for ion ﬂow or by
inducing structural rearrangements that block ion conduc-
tion, or both.
It is interesting to note that the HMA and rimantadine
binding sites both contain several hydrophobic residues and
the two residues they have in common are Leu52 and Val53.
Mutations of L(50–55)A that decreased hydrophobicity have
been shown to result in the loss of rimantadine sensitivity,
and other observed mutation with decreased hydrophobicity
also confers drug resistance in p7 (Foster et al., 2011). Since
the known inhibitors of p7 channel, although structurally very
different, contain a hydrophobic component, we believe one
of the key determinants of p7 allosteric inhibitors is
hydrophobic interaction. In the case of HMA, besides the
hydrophobic interactions of hexamethylene with Leu24,
Leu52 and Val53, the amiloride of HMA forms hydrogen
bond with Lys33 and interacts with Leu36 and Leu45 by Van
der Waals force (Fig. 2E). The extra polar interactions
between HMA and p7 may account for the stronger inhibi-
tion. Further functional validation of HMA binding would be
highly desirable to validate these interactions to provide a
future direction for structure-guided inhibitor design.
Finally, obtaining structural information of weak inhibitors
binding to ion channels is notoriously difﬁcult. The combined
use of NMR to identify the proximal ligand binding site and
MD simulation to reﬁne the channel-ligand complex as
demonstrated here for the HCV p7 channel represents an
effective solution to harvest useful information from many
known weak inhibitors of ion channels.
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